Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity.
Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity.
复制标题
DOI:
10.1073/pnas.2205085120
复制
发表时间:
2023-04-18
影响因子:
11.1
通讯作者:
中科院分区:
文献类型:
--
作者:
PD-L1 interaction with CD80 can be in cis or in trans, but how PD-L1 interacts with CD80 in vivo remains controversial. Specific blockade of cis PD-L1/CD80 interactions on APCs reduces tumor immunity, but the impact of general blockade of PD-L1/CD80 interactions on tumor immunity remains unclear. Our studies demonstrate that in vivo trans PD-L1/CD80 interactions do exist between T and tumor cells, and in vivo blockade of trans PD-L1/CD80 interactions or general PD-L1/CD80 interactions augment tumor immunity via expansion of IFN-γ-producing CD8+T cells and NOS2+macrophages in the tumor tissues. These results indicate that in vivo trans PD-L1/CD80 interactions between tumor and T cells are dominant over cis PD-L1/CD80 interactions. PD-L1 has two receptors: PD-1 and CD80. Previous reports assumed that PD-L1 and CD80 interacted in trans, but recent reports showed that only cis PD-L1/CD80 interactions existed, and prevention of cis PD-L1/CD80 interactions on antigen-presenting cells (APCs) reduced antitumor immunity via augmenting PD-L1/PD-1 and CD80/CTLA4 interactions between T and APCs. Here, using tumor-bearing mice capable of cis and trans or trans only PD-L1/CD80 interactions, we show that trans PD-L1/CD80 interactions do exist between tumor and T cells, and the effects of trans PD-L1/CD80 interactions require tumor cell expression of MHC-I and T cell expression of CD28. The blockade of PD-L1/CD80 interactions in mice with both cis and trans interactions or with only trans interactions augments antitumor immunity by expanding IFN-γ–producing CD8+ T cells and IFN-γ–dependent NOS2-expressing tumor-associated macrophages. Our studies indicate that although cis and trans PD-L1/CD80 interactions may have opposite effects on antitumor immunity, the net effect of blocking PD-L1/CD80 interactions in vivo augments CD8+ T cell-mediated antitumor immunity.
登录
查看更多内容
DOI:
10.4049/jimmunol.1402157
发表时间:
2015-01-15
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
Deng R;Cassady K;Li X;Yao S;Zhang M;Racine J;Lin J;Chen L;Zeng D
通讯作者:
Zeng D
影响因子:
32.4
作者:
Butte, Manish J.;Keir, Mary E.;Freeman, Gordon J.
通讯作者:
Freeman, Gordon J.
影响因子:
12.4
作者:
Erkes, Dan A.;Xu, Guangwu;Snyder, Christopher M.
通讯作者:
Snyder, Christopher M.
影响因子:
10.1
作者:
Chaudhri A;Xiao Y;Klee AN;Wang X;Zhu B;Freeman GJ
通讯作者:
Freeman GJ
影响因子:
15.3
作者:
Azuma, M;Yssel, H;Phillips, J H;Spits, H;Lanier, L L
通讯作者:
Lanier, L L